collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surfaces novel, investigational cancer immunotherapies are designed to achieve a clinically
meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Forward-Looking Statements
This communication relates to
the proposed transaction pursuant to the terms of the Agreement and Plan of Merger, dated June 15, 2023, by and among Coherus, Crimson Merger Sub I, Inc. (Merger Sub I), Crimson Merger Sub II, LLC (Merger
Sub II), and Surface. This communication includes includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and
Section 21E of the Securities Exchange Act of 1934, as amended about the proposed transaction between Coherus and Surface and the operations of the combined company that involve risks and uncertainties relating to future events and the future
performance of Surface and Coherus. Actual events or results may differ materially from these forward-looking statements. Words such as will, could, would, should, expect, plan,
anticipate, intend, believe, estimate, predict, project, potential, continue, future, opportunity, will likely
result, target, variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.
Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the proposed transaction and related matters, including, but not limited to, satisfaction of closing conditions to the proposed
transaction, prospective performance and opportunities with respect to Surface, Coherus or the combined company, post-closing operations and the outlook for the companies businesses; prospective developments or results in the pipelines of
Coherus, Surface or the combined company and expansion of Coherus I-O franchise; the prospects for approval of toripalimab; Surfaces, Coherus or the combined companys targets, plans,
objectives or goals for future operations, including those related to Surfaces and Coherus product candidates, research and development, product candidate introductions and product candidate approvals as well as cooperation in relation
thereto; projections of or targets for revenues, costs, and other financial measures; future economic performance and the assumptions underlying or relating to such statements. These statements are based on Surfaces and Coherus current
plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause
actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to
the timing for completion of the proposed transaction; uncertainties as to Surfaces ability to obtain the approval of Surfaces stockholders required to consummate the proposed transaction; the occurrence of events that may give rise to a
right of one or both of Surface and Coherus to terminate the merger agreement; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived on a timely basis or at all, including the possibility that a
governmental entity or regulatory authority may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of
predicting the timing or outcome of consents or regulatory approvals or actions, if any; the possibility that the proposed transaction may not be completed in the time frame expected by Surface and Coherus, or at all; the risk that Surface and
Coherus may not realize the anticipated benefits of the